Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds

Clinical and Experimental Immunology

Volumn 174, Issue 3, 2013, Pages 356-363

  Migita, K ^a   Izumi, Y ^a   Torigoshi, T ^a   Satomura, K ^a   Izumi, M ^a   Nishino, Y ^a   Jiuchi, Y ^a   Nakamura, M ^a   Kozuru, H ^a   Nonaka, F ^b   Eguchi, K ^b   Kawakami, A ^c   Motokawa, S ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b Sasebo Shiritsu Sogo Hospital   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

CP 690,550; INCB020850; Janus kinase; Rheumatoid arthritis; Signal transducer and activator of transcription

Indexed keywords

BARICITINIB; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE 3 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PF 956980; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TOFACITINIB; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM;

CP-690,550; INCB020850; JANUS KINASE; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION;

ARTHRITIS, RHEUMATOID; FIBROBLASTS; HUMANS; JANUS KINASES; ONCOSTATIN M; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; SYNOVIAL FLUID; SYNOVIAL MEMBRANE;

EID: 84886304076     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12190     Document Type: Article

References (32)

1. Heim MH. The JAK-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res 1999; 19:75-120.
2. Darnell JE Jr, Kerr IM, Stark GR. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415-1421.
3. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995; 270:794-797.
4. Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum 2003; 48:2092-2096.
5. Park SY, Saijo K, Takahashi T etal. Developmental defects of lymphoid cells in Jak-3 kinase-deficient mice. Immunity 1995; 3:771-782.
6. Macchi P, Villa A, Giliani S etal. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995; 377:65-68.
7. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009; 10:491-504.
8. Miyazaki T, Kawahara A, Fujii H etal. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 1994; 266:1045-1047.
9. Sweeney SE, Firestein GS. Signal transduction in rheumatoid arthritis. Curr Opin Rheumatol 2004; 16:231-237.
10. Pesu M, Candotti F, Husa M, Hofmann SR, Notarangelo LD, O'Shea JJ. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005; 203:127-142.
11. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008; 223:132-142.
12. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:335-341.
13. Fleischmann R, Kremer J, Cush J etal. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495-507.
14. van Vollenhoven RF, Fleischmann R, Cohen S etal. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508-519.
15. van der Heijde D, Tanaka Y, Fleischmann R etal. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65:559-570.
16. Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690, 550. Trends Pharmacol Sci 2011; 32:25-34.
17. Fridman JS, Scherle PA, Collins R etal. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010; 184:5298-5307.
18. Li WQ, Dehnade F, Zafarullah M. Oncostatin M-induced matrix metalloproteinase and tissue inhibitor of metalloproteinase-3 genes expression in chondrocytes requires Janus kinase/STAT signaling pathway. J Immunol 2001; 166:3491-3498.
19. Steele AJ, Prentice AG, Cwynarski K etal. The JAK-3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood 2010; 116:4569-4577.
20. Kok SH, Hong CY, Kuo MY etal. Oncostatin M-induced CCL2 transcription in osteoblastic cells is mediated by multiple levels of STAT-1 and STAT-3 signaling: an implication for the pathogenesis of arthritis. Arthritis Rheum 2009; 60:1451-1462.
21. Kerr C, Langdon C, Graham F, Gauldie J, Hara T, Richards CD. Adenovirus vector expressing mouse oncostatin M induces acute-phase proteins and TIMP-1 expression in vivo in mice. J Interferon Cytokine Res 1999; 19:1195-1205.
22. Hagihara K, Nishikawa T, Sugamata Y etal. Essential role of STAT3 in cytokine-driven NF-kappaB-mediated serum amyloid A gene expression. Genes Cells 2005; 10:1051-1063.
23. Bonilla-Hernán MG, Miranda-Carús ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. Rheumatology (Oxf) 2011; 50:1542-1550.
24. Ghoreschi K, Jesson MI, Li X etal. Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J Immunol 2011; 186:4234-4243.
25. Tanaka M, Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003; 149:39-52.
26. Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum 2003; 48:3404-3418.
27. Cawston TE, Curry VA, Summers CA etal. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum 1998; 41:1760-1771.
28. + T cells. Arthritis Rheum 2012; 64:1790-1798.
29. van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV etal. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48:2132-2145.
30. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228:273-287.
31. Alicea-Velázquez NL, Boggon TJ. The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets 2011; 12:546-555.
32. Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009; 10:356-360.